Clinical trials: Metastatic Clear Cell Renal Carcinoma
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Clear Cell Renal Cell Carcinoma
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
The main purpose of this study is to find out how useful dovitinib is when given as the initial treatment to participants with advanced kidney cancer, that has spread to other parts of the body.
- Trial name
- DILIGENCE-1 (NCT01791387)
- Testing
- Dovitinib
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Auckland District Health Board
Clear Cell Renal Cell Carcinoma
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.
- Trial name
- HARRIER (NCT07084909)
- Testing
- piflufolastat F 18
- Where
- 2 sites in United States
- Sponsor
- Lantheus Medical Imaging
Kidney Cancer
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00853021
- Testing
- aldesleukin, bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jorge A. Garcia, MD
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Renal Cell Carcinoma (Kidney Cancer)
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
- Trial name
- NCT07062549
- Testing
- 111In-XYIMSR-01
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Renal Cell Carcinoma, Nonclear Cell
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
1. There is no standard treatment option for non-clear cell renal cell carcinoma (RCC). 2. Patients with non-clear cell RCC is strongly assumed to have benefit from anti-VEGF treatment. 3.
- Conditions
- Renal Cell Carcinoma, Nonclear Cell, Temsirolimus Resistance
- Trial name
- NCT01798446
- Testing
- Axitinib
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Seoul National University Hospital
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue
- Trial name
- NCT03793166
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib
- Where
- 859 sites in United States, Puerto Rico
- Volunteers
- 1,175 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT03092856
- Testing
- Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- University of Southern California
Metastatic Clear Cell Renal Cancer
A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)
The purpose of this study is to investigate if 14 weeks of pazopanib therapy prior to surgery (nephrectomy) is of benefit to patients with metastatic renal cancer. Ninety-five patients will be recruited into his study.
- Trial name
- Panther (NCT01512186)
- Where
- 9 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- Queen Mary University of London
Clear Cell Renal Cell Carcinoma
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients…
- Trial name
- LAG-BOOST (NCT07223541)
- Testing
- Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
This study is testing a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread to other parts of the body (metastatic clear cell renal cell carcinoma).
- Trial name
- NCT07488572
- Testing
- Yivoximab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Clear-cell Metastatic Renal Cell Carcinoma
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Two randomized trials in the cytokine era clearly showed that cytoreductive nephrectomy (CN) had a role in metastatic renal cell carcinoma (mRCC) increasing life expectancy.
- Trial name
- TARIBO (NCT02535351)
- Testing
- sunitinib or pazopanib, Cytoreductive nephrectomy
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in the body (advanced/metastatic).
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05122546
- Testing
- Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT05361720
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced or Metastatic Renal Cell Carcinoma
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after…
- Trial name
- CaboPoint (NCT03945773)
- Testing
- Cabozantinib
- Where
- 40 sites in Austria, France and 5 more
- Volunteers
- 127 people
- Sponsor
- Ipsen
Neoplasms, Kidney Neoplasms
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up.
- Conditions
- Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms
- Trial name
- NCT06676527
- Testing
- Follow-up study of the treated cohort
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Jinling Hospital, China
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
SLM + Axitinib for Clear Cell RCC
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it…
- Trial name
- NCT02535533
- Testing
- Selenomethionine (SLM), Axitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mohammed Milhem
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Carcinoma, Renal Cell
Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
This study will gather data on potential biomarkers in the treatment of advanced renal cell carcinoma (kidney cancer) and investigate their use as indicators of disease response.
- Trial name
- NCT01107509
- Testing
- everolimus
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- St. Joseph's Healthcare Hamilton